Does LORLATINIB Cause Dyslipidaemia? 67 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 67 reports of Dyslipidaemia have been filed in association with LORLATINIB (Lorbrena). This represents 1.2% of all adverse event reports for LORLATINIB.
67
Reports of Dyslipidaemia with LORLATINIB
1.2%
of all LORLATINIB reports
5
Deaths
12
Hospitalizations
How Dangerous Is Dyslipidaemia From LORLATINIB?
Of the 67 reports, 5 (7.5%) resulted in death, 12 (17.9%) required hospitalization, and 2 (3.0%) were considered life-threatening.
Is Dyslipidaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LORLATINIB. However, 67 reports have been filed with the FAERS database.
What Other Side Effects Does LORLATINIB Cause?
Death (1,050)
Neoplasm progression (633)
Off label use (394)
Weight increased (306)
Hallucination (290)
Blood cholesterol increased (281)
Dyspnoea (223)
Oedema peripheral (198)
Oedema (195)
Fatigue (188)
What Other Drugs Cause Dyslipidaemia?
OLANZAPINE (230)
ROSUVASTATIN (206)
ARIPIPRAZOLE (185)
METHOTREXATE (175)
QUETIAPINE (161)
ATORVASTATIN (155)
RISPERIDONE (154)
METFORMIN (151)
TACROLIMUS (149)
ZIPRASIDONE (149)
Which LORLATINIB Alternatives Have Lower Dyslipidaemia Risk?
LORLATINIB vs LORMETAZEPAM
LORLATINIB vs LORNOXICAM
LORLATINIB vs LOSARTAN
LORLATINIB vs LOSARTAN\LOSARTAN
LORLATINIB vs LOTEPREDNOL ETABONATE